Acute Kidney Injury Secondary to Pegylated Liposomal Doxorubicin-Associated Renal-limited Thrombotic Microangiopathy

The emergence of pegylated liposomal doxorubicin (PLD) as a preferred treatment for various malignancies, because of its reduced cardiotoxicity compared with conventional doxorubicin, has raised significant interest. However, the association between PLD and thrombotic microangiopathy (TMA) remains a...

書誌詳細
出版年:	Kidney Medicine
主要な著者:	Tarek S. Karam, Mrinalini Sarkar, Jonathan E. Zuckerman
フォーマット:	論文
言語:	英語
出版事項:	Elsevier 2025-05-01
主題:	Doxil kidney biopsy onconephrology pegylated liposomal doxorubicin thrombotic microangiopathy (TMA) renal pathology
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S2590059525000342

類似資料

The supramolecular processing of liposomal doxorubicin hinders its therapeutic efficacy in cells
著者:: Annalisa Carretta, 等
出版事項: (2024-09-01)

The outcome of thrombotic microangiopathy in kidney transplant recipients
著者:: Kanza Haq, 等
出版事項: (2024-11-01)

Association of thrombotic microangiopathy with interferon therapy for hepatitis B: a case report
著者:: Shan Wei, 等
出版事項: (2024-07-01)

Clinical value of the renal pathologic scoring system in complement-mediated thrombotic microangiopathy
著者:: Fei-Fei Chen, 等
出版事項: (2023-12-01)

Thrombotic microangiopathy multidisciplinary assessment team: demographics, final diagnosis, treatment, and outcomes
著者:: Matthew Nguyen, 等
出版事項: (2025-09-01)

Renal involvement in solid cancers: epidemiological, clinical and histological characteristics study of 154 onconephrology patients
著者:: Victor Gueutin, 等
出版事項: (2024-10-01)

Case report: Successful treatment of renal-limited thrombotic microangiopathy secondary to chronic lymphocytic leukemia
著者:: Kristina Nasr, 等
出版事項: (2024-08-01)

Place of pegylated liposomal doxorubicin in the therapy of metastatic breast cancer
著者:: E. V. Artamonova
出版事項: (2016-09-01)

Evaluation of Pegylated Liposomal Doxorubicin in the Treatment Of Both Platinum- and Paclitaxel-Refractory Epithelial Ovarian Cancer
著者:: Hao Lin, 等
出版事項: (2004-09-01)

Drug-induced de novo thrombotic microangiopathy diagnosed 2 years after renal transplantation: a case report and literature review
著者:: Keisuke Ozaki, 等
出版事項: (2023-01-01)

Microangiopathy in multiple myeloma: a case of carfilzomib-induced secondary thrombotic microangiopathy successfully treated with plasma exchange and complement inhibition
著者:: Lorenzo Catanese, 等
出版事項: (2023-06-01)

Pseudo-Thrombotic Microangiopathy (Pseudo-TMA): a rare manifestation of vitamin B12 deficiency in a child
著者:: Mohd Arif, 等
出版事項: (2025-06-01)

Pregnancy in Complement-Mediated Thrombotic Microangiopathy: Maternal and Neonatal OutcomesPlain Language Summary
著者:: Natalja Haninger-Vacariu, 等
出版事項: (2023-07-01)

Reducing toxicity and enhancing efficacy of doxorubicin by liposomal doxorubicin and aprepitant in breast cancer
著者:: Atefeh Ghahremanloo, 等
出版事項: (2025-03-01)

Diffuse Erythematous Follicular Eruption Induced by Pegylated Liposomal Doxorubicin
著者:: Zhong L, 等
出版事項: (2025-04-01)

Efficacy and safety of pegylated liposomal doxorubicin and epirubicin as neoadjuvant chemotherapy for breast cancer
著者:: Yuanyuan Shen, 等
出版事項: (2024-12-01)

An Open-Label Study of Pegylated Liposomal Doxorubicin, Vincristine, and Reduced-Dose Dexamethasone Combination Therapy in Newly Diagnosed Multiple Myeloma Patients in the Chinese Population
著者:: Yang SHEN, Zhixiang SHEN, Bin JIANG, 等
出版事項: (2009-12-01)

A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML
著者:: Brian A. Jonas, 等
出版事項: (2023-01-01)

Neoadjuvant Combination Chemotherapy with Pegylated Liposomal Doxorubicin and Vinorelbine for Locally Advanced Breast Cancer
著者:: Zhen-zhou SHEN, 等
出版事項: (2010-02-01)

Thrombotic microangiopathy in children: Redefining hemolytic uremic syndrome, thrombotic thrombocytopenic purpura and related disorders
著者:: Mamta Manglani, 等
出版事項: (2024-03-01)

Bevacizumab-Induced Thrombotic Microangiopathy (TMA) in Metastatic Lung Adenocarcinoma Patients Receiving Nivolumab Combined with Bevacizumab, Carboplatin and Paclitaxel: Two Case Reports
著者:: Ping-Chih Hsu, 等
出版事項: (2023-01-01)

Meta-Analysis of Trials Comparing Gemcitabine and Pegylated Liposomal Doxorubicin for Treatment in Women with Progressive or Recurrent Ovarian Cancer
著者:: Xia LIU, 等
出版事項: (2009-12-01)

PEGylated versus Non-PEGylated pH-Sensitive Liposomes: New Insights from a Comparative Antitumor Activity Study
著者:: Shirleide Santos Nunes, 等
出版事項: (2022-01-01)

Pegylated Liposomal Doxorubicin as a Single Agent or as Combination Therapy with Carboplatin in Patients with Recurrent or Refractory Epithelial Ovarian Cancer
著者:: Keng SHEN, 等
出版事項: (2009-12-01)

The role of size in PEGylated liposomal doxorubicin biodistribution and anti‐tumour activity
著者:: Saba Dadpour, 等
出版事項: (2022-09-01)

Extracorporeal Elimination of Circulating Pegylated Liposomal Doxorubicin (PLD) to Enhance the Benefit of Cytostatic Therapy in Platinum-Resistant Ovarian Cancer Patients
著者:: Ondřej Kubeček, 等
出版事項: (2015-07-01)

Effective Management of Carfilzomib-Induced Thrombotic Microangiopathy in Multiple Myeloma Using Eculizumab
著者:: Jennifer Kim, 等
出版事項: (2025-06-01)

Thrombotic microangiopathy associated with Valproic acid toxicity
著者:: Sean A. Hebert, 等
出版事項: (2017-08-01)

Phase I Trial of Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Advanced Soft Tissue Sarcoma
著者:: Ye T, 等
出版事項: (2025-08-01)

Lupus nephritis and thrombotic microangiopathy: A review
著者:: Larisa A. Bobrova, 等
出版事項: (2024-01-01)

Impact of PEGylated Liposomal Doxorubicin and Carboplatin Combination on Glioblastoma
著者:: Mohsen Ghaferi, 等
出版事項: (2022-10-01)

Effect of blood groups on acquired and congenital thrombotic thrombocytopenic purpura and clinical correlation: Multi-center Turkish cohort study
著者:: Cevat İlteriş Kıkılı, 等
出版事項: (2025-01-01)

Adipose tissue area is a predictive biomarker for the efficacy of pegylated liposomal doxorubicin in platinum‐refractory/resistant ovarian cancer
著者:: Hiroyuki Yoshida, 等
出版事項: (2023-07-01)

Rare Case of Congenital Thrombotic Thrombocytopenic Purpura Presenting as Posttransplant Thrombotic Microangiopathy
著者:: Akila Viswanathan, 等
出版事項: (2024-12-01)

Recent Preclinical and Clinical Progress in Liposomal Doxorubicin
著者:: Kenan Aloss, 等
出版事項: (2023-03-01)

Pegylated liposomal doxorubicin does not affect cardiac function in patients treated for gynecologic malignancies
著者:: Khrystyna Levytska, 等
出版事項: (2025-04-01)

Thrombotic microangiopathy associated with lenvatinib therapy
著者:: Macarena Contreras Angulo, 等
出版事項: (2023-04-01)

Adjuvant Antitumor Immunity Contributes to the Overall Antitumor Effect of Pegylated Liposomal Doxorubicin (Doxil<sup>®</sup>) in C26 Tumor-Bearing Immunocompetent Mice
著者:: Takuma Takayama, 等
出版事項: (2020-10-01)

A comprehensive model for assessing and classifying patients with thrombotic microangiopathy: the TMA-INSIGHT score
著者:: Vanessa Vilani Addad, 等
出版事項: (2023-11-01)

Renal survival and improvement in younger malignant hypertension patients with thrombotic microangiopathy
著者:: Jianbo Li, 等
出版事項: (2025-12-01)